Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JTC posts double-digit H1 revenue growth

(Sharecast News) - Fund administrator JTC reported a 17.3% year-on-year increase in interim revenues to £172.6m on Tuesday, driven by strong organic growth and record new business wins. JTC said underlying earnings had risen 15.1% to £56.5m in the six months ended 30 June, with a margin of 32.8%, while underlying basic earnings per share improved 7.1% to 21.3p. It also declared a 5.0p interim dividend, up 16.3% on the prior year.

However, net debt increased to £250.7m, reflecting acquisition activity and strategic investments, while reported profits sank 62.6% year-on-year to £6.9m, impacted by non-underlying items including share-based payments and integration costs.

The FTSE 250-listed group stated that its multi-year 'Cosmos Era' business plan was ahead of schedule, with full-year expectations unchanged. Post-period end, JTC completed the acquisition of Citi Trust and proposed a £20m deal for Kleinwort Hambros Trust Company, expected to complete in Q4 and be earnings accretive in 2026.

JTC also highlighted that full-year expectations remained unchanged, in line with management guidance.

CEO Nigel Le Quesne said: "We are pleased with the growth and momentum of the Group in the first half of 2025 - another record performance. Set against the backdrop of a challenging market, our highly diverse and international client base, paired with the benefit of our diversified and sustainable business model, is reaping rewards.

"The second half of our financial year has started well with good new business wins across both divisions and the announcement of our proposed acquisition of KHT. We remain confident that we will deliver the Cosmos era business plan ahead of schedule, before the end of 2027."

As of 0805 BST, JTC shares were up 2.11% at 1,358p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.